Abstract:BackgroundBetween 25%-50% of patients hospitalized with (COVID-19) suffer cardiovascular events. Limited information is available to identify those at greatest risk for cardiac complications.ObjectivesObjectives were to analyze risk factors associated with cardiovascular events (CE); analyze whether risk factors and outcomes were influenced by race; and analyze survival differences among various groups.MethodsThis retrospective cohort study of 700 inpatients with COVID-19 was conducted at nine hospitals within a large urban midwestern city. Data was collected from March 9, 2020, to June 20, 2020. Inclusion criteria included all COVID-19 inpatients and excluded non-inpatients. Predictor variables included demographics, comorbidities, and current clinical data. The outcomes were heart failure (HF), deep-vein thrombosis, myocardial infarction, pulmonary edema, stroke, cardiomyopathy, myocarditis, reduced ejection fraction, cardiac arrhythmias, cardiogenic shock, and cardiac arrest. Pearson's correlation coefficients were used to evaluate the correlation between different variables. Multiple logistics regression analyses were conducted to examine which variables predict cardiovascular events for the entire cohort, African American patients, and white patients, respectively. Mann-Whitney U, Chi-square, or Fisher's exact tests were used to examine differences in groups with and without CE and Kaplan-Meier was conducted for survival comparisons between groups.ResultsOf 700 COVID-19 positive inpatients, 126 experienced cardiovascular events and 574 did not. The incidence of cardiovascular events in our sample population was 18%. As shown in Table 1, we found the following factors were highly associated with the odds of new-onset of CEs: advanced age in years, males, non-Hispanic African American, presence of comorbidities, and decreased saturation levels. Numerous laboratory values were significantly associated with the risk of CEs (Table 1).African Americans had greater odds of CEs in the presence of diabetes and cardiovascular comorbidities (p=0.008, p=0.014, respectively). However, multiple logistics analysis was used to examine the joint effect of the risk factors which suggested that lower serum albumin and neoplastic/immune compromised diseases count were highly associated with CEs for African American COVID-19 inpatients (p=0.001, p=0.044, respectively). SaO2/FiO2 ratio and cardiovascular comorbidities were significantly associated with CEs for white inpatients (p=<0.001, p=0.007, respectively).As shown in Figure 1, Kaplan-Meier survival analysis revealed inpatients with CEs had a much higher mortality rate than those without CEs (45.2% vs. 8.7%). Median survival for patients with CEs was 18 days as opposed to 100 days for those that did not experience CEs. African Americans with CEs experienced higher mortality than those without CEs (43.9% vs. 7.8%). White COVID-19 inpatients' mortality rates were 46.3% and 9.0% for those with and without CEs, respectively.Of the 126 COVID-19 inpatients who had a CE, 14.3% had cardiac arrhythmias and 8.7% had new onset of HF diagnoses, and 4.8% had acute myocardial infarctions.ConclusionMultiple risk factors for CEs and death were identified in this sample of hospitalized patients with COVID-19, and mortality was increased significantly in those inpatients who had CEs. HF, cardiac arrhythmia, and acute myocardial infarction were the most frequently cited CEs implicating the need for long-term follow-up.

Burden of cardiovascular disease on coronavirus disease 2019 hospitalizations in the USA

Impact of Cardiovascular Disease on Clinical Characteristics and Outcomes of Coronavirus Disease 2019 (COVID-19).

A Meta-Analysis on the Risk Factors Adjusted Association Between Cardiovascular Disease and COVID-19 Severity.

Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry)

The Burden of Cardiovascular Disease in the Post-COVID Era

The course of COVID-19 infection in patients with cardiovascular diseases

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic

The Association of Cerebrovascular Disease with Adverse Outcomes in COVID-19 Patients: A Meta-Analysis Based on Adjusted Effect Estimates

Prevalence of coronary artery disease among COVID-19 patients: a systematic review and meta-analysis

P014. Risk Factors for Cardiovascular Events In Hospitalized Patients with COVID-19

Long-term cardiovascular outcomes of COVID-19

Impact of the COVID-19 pandemic on in-hospital mortality in cardiovascular disease: a meta-analysis

A systematic review of covid-19 impact on cardiovascular diseases

Cardiovascular risk and complications associated with COVID-19

Abstract 11754: Trends in Cardiovascular Mortality Before and During the COVID-19 Pandemic

Cardiovascular manifestations in COVID-19 patients: A systematic review and meta-analysis

Brief report: Effect of cardiac multi-morbidity on COVID hospitalization outcomes

COVID-19 Associated Cardiovascular Disease—Risks, Prevention and Management: Heart at Risk Due to COVID-19

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

The Clinical Impact of SARS-CoV-2 on Hypertrophic Cardiomyopathy

Cardiovascular comorbidity and its impact on patients with COVID-19